Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

Jacek Gronwald, Andre Robidoux, Charmaine Kim-Sing, Nadine Tung, Henry T. Lynch, William D. Foulkes, Siranoush Manoukian, Peter Ainsworth, Susan L. Neuhausen, Rochelle Demsky, Andrea Eisen, Christian F. Singer, Howard Saal, Leigha Senter, Charis Eng, Jeffrey Weitzel, Pal Moller, Dawna M. Gilchrist, Olufunmilayo Olopade, Ophira GinsburgPing Sun, Tomasz Huzarski, Jan Lubinski, Steven A. Narod, David Euhus, Judy Garber, Gad Rennert, Kevin Sweet, Ruth Gershoni-Baruch, Christine Rappaport, Edmond Lemire, Lovise Maehle, Dominique Stoppa-Lyonnet, Mary Daly, Sofia Merajver, Ava Kwong, Louise Bordeleau, Carey A. Cullinane, Eitan Friedman, Wendy McKinnon, Marie Wood, Daniel Rayson, Wendy Meschino, Jane McLennan, Josephine Wagner Costalas, Robert E. Reilly, Tuya Pal, Susan Vadaparampil, Kenneth Offit, Mark Robson, Noah Kauff, Jan Klijn, Claudine Isaacs, Fergus Couch, Cezary Cybulski, Tomasz Byrski, Ania Jakubowska, Seema Panchal, Sonia Nanda, Aletta Poll, Kelly Metcalfe, Barry Rosen, Susan Randall Armel, Albert Chudley, Gareth Evans, Joanne Blum, Beth Karlan, Dana Zakalik, John Lunn, Talia Donenberg, Barbara Pasini, Raluca N. Kurz, Taya Fallen

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Fingerprint

Dive into the research topics of 'Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers'. Together they form a unique fingerprint.

Medicine & Life Sciences